immune checkpoint inhibitor
C2Technical / Scientific
Definition
Meaning
A type of drug that blocks proteins on immune cells, allowing them to attack cancer cells more effectively.
A class of immunotherapeutic agents designed to disrupt inhibitory pathways (checkpoints) used by cancer cells to evade detection and destruction by the body's T-cells, thereby reinvigorating the immune response against tumours.
Linguistics
Semantic Notes
A compound noun, highly domain-specific to oncology and immunology. The term is a hyponym of 'immunotherapy' and 'biologic therapy'. The 'checkpoint' metaphor refers to regulatory mechanisms that prevent autoimmunity but are exploited by tumours.
Dialectal Variation
British vs American Usage
Differences
No significant lexical or spelling differences. The term is used identically in international medical literature.
Connotations
Identical technical and clinical connotations.
Frequency
Equally low in general discourse, but standard and high-frequency within the specialised fields of oncology and immunology in both regions.
Vocabulary
Collocations
Grammar
Valency Patterns
N + for + [condition] (an immune checkpoint inhibitor for melanoma)N + that + [clause] (an inhibitor that blocks CTLA-4)Adj + N (a monoclonal antibody immune checkpoint inhibitor)Vocabulary
Synonyms
Strong
Neutral
Weak
Vocabulary
Antonyms
Usage
Context Usage
Business
Rare, except in biotech/pharma investment reports discussing drug pipelines and market potential.
Academic
The primary context. Ubiquitous in medical, biological, and oncological research papers, clinical trial reports, and reviews.
Everyday
Extremely rare. Might be encountered in patient information leaflets or news articles about cancer treatments.
Technical
The standard register. Used by clinicians, oncologists, researchers, and healthcare professionals in diagnosis, treatment planning, and discussion of adverse effects.
Examples
By Part of Speech
verb
British English
- The treatment aims to inhibit the checkpoint.
American English
- The drug inhibits the PD-1 pathway.
adverb
British English
- The T-cells responded immunologically.
American English
- The tumour was treated immunologically.
adjective
British English
- They discussed immune-checkpoint therapy.
American English
- Checkpoint inhibition is a revolutionary approach.
Examples
By CEFR Level
- Doctors have new medicines for cancer.
- Some new cancer drugs help your own body fight the disease.
- Immunotherapy, including drugs called checkpoint inhibitors, represents a major advance in cancer treatment.
- The patient's metastatic melanoma showed a marked clinical response following administration of an anti-PD-1 immune checkpoint inhibitor, although they subsequently developed immune-related colitis.
Learning
Memory Aids
Mnemonic
Imagine a guard (immune system) whose 'OFF' button (checkpoint) is held down by a criminal (cancer). An INHIBITOR is a tool that stops the criminal from pressing that button, letting the guard fight.
Conceptual Metaphor
THE IMMUNE SYSTEM IS A SECURITY SYSTEM; CANCER IS A CRIMINAL DISGUISING ITSELF; THE DRUG IS A TOOL TO REMOVE THE DISGUISE.
Watch out
Common Pitfalls
Translation Traps (for Russian speakers)
- Avoid calquing as 'иммунный чекпоинт ингибитор' in non-technical contexts. The established term in Russian is 'ингибитор иммунных контрольных точек'.
- The word 'checkpoint' is a metaphorical term, not related to military or border checkpoints (контрольно-пропускной пункт).
Common Mistakes
- Mispronouncing 'immune' as /ˈɪm.juːn/ (correct: /ɪˈmjuːn/).
- Incorrect word order: 'checkpoint immune inhibitor'.
- Using as a countable noun without an article: '*Patient received immune checkpoint inhibitor' instead of '...an immune checkpoint inhibitor'.
Practice
Quiz
What is the primary mechanism of action of an immune checkpoint inhibitor?
FAQ
Frequently Asked Questions
No, it is fundamentally different. Chemotherapy directly kills fast-dividing cells (including healthy ones), while checkpoint inhibitors are immunotherapies that enable the patient's own immune system to target cancer cells.
Common examples include pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), and atezolizumab (Tecentriq).
It refers to natural regulatory proteins (like PD-1 or CTLA-4) that act as 'brakes' or checkpoints on the immune system to prevent it from attacking the body's own cells. Cancers exploit these checkpoints to hide.
Yes, they can cause unique side effects called immune-related adverse events (irAEs), where the activated immune system attacks healthy tissues, potentially affecting organs like the colon, liver, lungs, or endocrine glands.